A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells

Journal of Biological Chemistry

Volumn 289, Issue 44, 2014, Pages 30443-30458

  Bailey, Tameka A ^a   Luan, Haitao ^a   Tom, Eric ^a   Bielecki, Timothy Alan ^a   Mohapatra, Bhopal ^a   Ahmad, Gulzar ^a   George, Manju ^a   Kelly, David L ^a,b   Natarajan, Amarnath ^a,b   Raja, Srikumar M ^a,b   Band, Vimla ^a,b   Band, Hamid ^a,b  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; CELLS; CHEMICAL ACTIVATION; DISEASES; ENZYME INHIBITION; ENZYMES; PROTEINS;

BREAST CANCER CELLS; ENDOCYTIC RECYCLING; G PROTEIN COUPLED RECEPTORS; KINASE INHIBITORS; ONCOGENIC POTENTIAL; POSITIVE FEEDBACK LOOP; PROTEIN KINASE C; SELECTIVE INHIBITORS;

RECYCLING;

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; TANESPIMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CARBAZOLE DERIVATIVE; ERBB2 PROTEIN, HUMAN; INDOLE DERIVATIVE; MACROCYCLIC LACTAM; PRKCA PROTEIN, HUMAN; PRKCD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RO 31-8220;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENDOSOME; ENZYME ACTIVATION; GENE SILENCING; GENETIC MANIPULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; ONCOGENE NEU; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TARGETING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG EFFECTS; DRUG SCREENING; ENDOCYTOSIS; FEEDBACK SYSTEM; FEMALE; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CARBAZOLES; CARCINOGENESIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOCYTOSIS; ENDOSOMES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; INDOLES; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTOR, ERBB-2;

EID: 84908605965     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.608992     Document Type: Article

References (115)

1. Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., and Cooper, C. S. (2010) A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59-64
2. Baselga, J., and Swain, S. M. (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463-475
3. Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., and Neckers, L. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. U.S.A. 99, 12847-12852
4. Zhou, P., Fernandes, N., Dodge, I. L., and Reddi, A. L., Rao, N., Safran, H., DiPetrillo, T. A., Wazer, D. E., Band, V., and Band, H. (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J. Biol. Chem. 278, 13829-13837
5. Neckers, L. (2003) Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. 10, 733-739
6. Sharp, S., and Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95, 323-348
7. Münster, P. N., Basso, A., Solit, D., Norton, L., and Rosen, N. (2001) Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res. 7, 2228-2236
8. Ohba, S., Hirose, Y., Yoshida, K., Yazaki, T., and Kawase, T. (2010) Inhibition of 90-kDa heat shock protein potentiates the cytotoxicity of che-motherapeutic agents in human glioma cells. J. Neurosurg. 112, 33-42
9. Lu, X., Xiao, L., Wang, L., and Ruden, D. M. (2012) Hsp90 inhibitors and drug resistancein cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 83, 995-1004
10. Raja, S.M., Clubb, R.J., Bhattacharyya, M., Dimri, M., Cheng, H., Pan, W., Ortega-Cava, C., Lakku-Reddi, A., Naramura, M., Band, V., and Band, H. (2008) A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol. Ther. 7, 1630-1640
11. Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N, D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., Ma, W., Patil, S., Norton, L., Hannah, A. L., and Hudis, C. (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139
12. Modi, S., and Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N, Norton, L., Cropp, G. F., Johnson, R. G., Hannah, A. L., and Hudis, C. A. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 25, 5410-5417
13. Widakowich, C., Dinh, P., de Azambuja, E., Awada, A., and Piccart-Gebhart, M. (2008) HER-2 positive breast cancer: what else beyond trastu-zumab-based therapy? Anticancer Agents Med. Chem. 8, 488-496
14. Zsebik, B., Citri, A., Isola, J., Yarden, Y., Szöllosi, J., and Vereb, G. (2006) Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol. Lett. 104, 146-155
15. Sorkin, A., and Goh, L. K. (2008) Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 314, 3093-3106
16. Vaidyanath, A., Hashizume, T., Nagaoka, T., Takeyasu, N, Satoh, H, Chen, L., Wang, J., Kasai, T., Kudoh, T., Satoh, A., Fu, L., and Seno, M. (2011) Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. J. Cell Mol. Med. 15, 2525-2538
17. Henriksen, L., and Grandal, M. V., Knudsen, S. L., van Deurs, B., and Grøvdal, L. M. (2013) Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One 8, e58148
18. Roepstorff, K., Grøvdal, L., Grandal, M., Lerdrup, M., and van Deurs, B. (2008) Endocytic down-regulation of ErbB receptors: mechanisms and relevance in cancer. Histochem. Cell Biol. 129, 563-578
19. Mohapatra, B., Ahmad, G., Nadeau, S., Zutshi, N, An, W., Scheffe, S., Dong, L., Feng, D., Goetz, B., Arya, P., Bailey, T. A., Palermo, N, Borgstahl, G. E., Natarajan, A., Raja, S. M., Naramura, M., Band, V., and Band, H. (2013) Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim. Biophys. Acta 1833, 122-139
20. Roepstorff, K., Grandal, M.V., Henriksen, L., Knudsen, S. L., Lerdrup, M., Grøvdal, L., Willumsen, B. M., and van Deurs, B. (2009) Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10, 1115-1127
21. Sigismund, S., Confalonieri, S., Ciliberto, A., Polo, S., Scita, G., and Di Fiore, P. P. (2012) Endocytosis and signaling: cell logistics shape the eu-karyotic cell plan. Physiol Rev. 92, 273-366
22. Waterman, H., Sabanai, I., Geiger, B., and Yarden, Y. (1998) Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273, 13819-13827
23. Lee, K. F., Simon, H., Chen, H, Bates, B., Hung, M. C, and Hauser, C. (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398
24. Park, S. K., Miller, R., Krane, I., and Vartanian, T. (2001) The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J. Cell Biol. 154, 1245-1258
25. Ursini-Siegel, J., Schade, B., and Cardiff, R. D., and Muller, W. J. (2007) Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 7, 389-397
26. Sliwkowski, M. X., Schaefer, G., Akita, R. W., and Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., 3rd (1994) Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269, 14661-14665
27. Magnifico, A., Tagliabue, E., Ardini, E., Casalini, P., and Colnaghi, M. I., and Ménard, S. (1998) Heregulin β1 induces the down-regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein. FEBSLett. 422, 129-131
28. King, C. R., Borrello, I., Bellot, F., Comoglio, P., and Schlessinger, J. (1988) Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. Embo J. 7, 1647-1651
29. Sorkin, A., Di Fiore, P. P., and Carpenter, G. (1993) The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 8, 3021-3028
30. Vartanian, T., Goodearl, A., Viehöver, A., and Fischbach, G. (1997) Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J. Cell Biol. 137, 211-220
31. Liu, Y., and Tao, Y. M., Woo, R. S., Xiong, W. C., and Mei, L. (2007) Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons. Biochem. Biophys. Res. Commun. 354, 505-510
32. Sidiropoulos, P. N, Miehe, M., Bock, T., Tinelli, E., Oertli, C. I., Kuner, R., Meijer, D., Wollscheid, B., Niemann, A., and Suter, U. (2012) Dynamin 2 mutations in Charcot-Marie-Tooth neuropathy highlight the importance of clathrin-mediated endocytosis in myelination. Brain 135, 1395-1411
33. Zhong, C., Du, C., Hancock, M., Mertz, M., and Talmage, D. A., and Role, L. W. (2008) Presynaptic type III neuregulin 1 is required for sustained enhancement of hippocampal transmission by nicotine and for axonal targeting of α7 nicotinic acetylcholine receptors. J. Neurosci. 28, 9111-9116
34. Yang, X. L., and Huang, Y. Z., Xiong, W. C., and Mei, L. (2005) Neuregulin-induced expression of the acetylcholine receptor requires endocytosis of ErbB receptors. Mol. Cell Neurosci. 28, 335-346
35. Worthylake, R., and Wiley, H. S. (1997) Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu. J. Biol. Chem. 272, 8594-8601
36. Worthylake, R., and Opresko, L. K., and Wiley, H. S. (1999) ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274, 8865-8874
37. Baulida, J., and Kraus, M. H., Alimandi, M., Di Fiore, P. P., and Carpenter, G. (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271, 5251-5257
38. Meijer, I. M., van Rotterdam, W., van Zoelen, E. J., and van Leeuwen, J. E. (2012) Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. Cell Signal. 24, 1981-1988
39. Wang, Z., Zhang, L., Yeung, T. K., and Chen, X. (1999) Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 het-erodimers in response to EGF stimulation. Mol. Biol. Cell. 10, 1621-1636
40. Stern, D. F., Heffernan, P.A., and Weinberg, R. A. (1986) p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell Biol. 6, 1729-1740
41. Mosesson, Y., Mills, G.B., and Yarden, Y. (2008) Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer. 8, 835-850
42. Watanabe, T. M., and Higuchi, H. (2007) Stepwise movements in vesicle transport of HER2 by motor proteins in living cells. Biophys. J. 92, 4109-4120
43. Zhu, W., Okollie, B., and Artemov, D. (2007) Controlled internalization of Her-2/neu receptors by cross-linking for targeted delivery. Cancer Biol. Ther. 6, 1960-1966
44. Friedman, L. M., Rinon, A., Schechter, B., Lyass, L., Lavi, S., Bacus, S. S., Sela, M., and Yarden, Y. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 102, 1915-1920
45. Maier, L. A., and Xu, F. J., Hester, S., Boyer, C. M., McKenzie, S., and Bruskin, A. M., Argon, Y., and Bast, R. C, Jr. (1991) Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/ neu gene product c-erbB-2. Cancer Res. 51, 5361-5369
46. Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C, Sliwkowski, M. X., Klumperman, J., and Scheller, R. H. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell. 15, 5268-5282
47. Hashizume, T., Fukuda, T., Nagaoka, T., Tada, H., Yamada, H., Watanabe, K., Salomon, D. S., and Seno, M. (2008) Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol. Int. 32, 814-826
48. Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., and Yarden, Y. (2013) Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc. Natl. Acad. Sci. U.S.A. 110, 8170-8175
49. Lerdrup, M., Bruun, S., Grandal, M. V., Roepstorff, K., and Kristensen, M. M., Hommelgaard, A. M., and van Deurs, B. (2007) Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C terminus. Mol. Biol. Cell. 18, 3656-3666
50. Lerdrup, M., and Hommelgaard, A. M., Grandal, M., and van Deurs, B. (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome-de-pendent way. J. Cell Sci. 119, 85-95
51. Cortese, K., and Howes, M. T., Lundmark, R., Tagliatti, E., Bagnato, P., Petrelli, A., Bono, M., McMahon, H. T., Parton, R. G., and Tacchetti, C. (2013) The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Mol. Biol. Cell. 24, 129-144
52. Vuong, T. T., Berger, C, Bertelsen, V., Rødland, M. S., Stang, E., and Madshus, I. H. (2013) Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes. Exp Cell Res. 319, 32-45
53. Marx, C, and Held, J. M., Gibson, B. W., and Benz, C. C. (2010) ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res. 70, 3709-3717
54. Barr, D. J., Ostermeyer-Fay, A. G., Matundan, R. A., and Brown, D. A. (2008) Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. J Cell Sci. 121, 3155-3166
55. Pedersen, N. M., and Madshus, I. H., Haslekås, C, and Stang, E. (2008) Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol. Cancer Res. 6, 491-500
56. Nishimura, M., and Shin, M. S., Singhirunnusorn, P., Suzuki, S., Kawanishi, M., Koizumi, K., Saiki, I., and Sakurai, H. (2009) TAK1-mediated serine/ threonine phosphorylation of epidermal growth factor receptor via p38/ extracellular signal-regulated kinase: NF-{κ}B-independent survival pathways in tumor necrosis factor α signaling. Mol. Cell Biol. 29, 5529-5539
57. Tong, J., Taylor, P., Peterman, S.M., Prakash, A., and Moran, M.F. (2009) Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol. Cell Proteomics 8, 2131-2144
58. Zwang, Y., and Yarden, Y. (2006) p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. Embo J.25, 4195-4206
59. Winograd-Katz, S. E., and Levitzki, A. (2006) Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25, 7381-7390
60. Bao, J., Alroy, I., Waterman, H., Schejter, E. D., Brodie, C, Gruenberg, J., and Yarden, Y. (2000) Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J. Biol. Chem. 275, 26178-26186
61. Lladó, A., Tebar, F., Calvo, M., Moretó, J., Sorkin, A., and Enrich, C. (2004) Protein kinase CS-calmodulin crosstalk regulates epidermal growth factor receptor exit from early endosomes. Mol. Biol. Cell. 15, 4877-4891
62. Lladó, A., Timpson, P., Vilà de Muga, S., Moretó, J., Pol, A., Grewal, T., Daly, R. J., Enrich, C, and Tebar, F. (2008) Protein kinase CS and calmodulin regulate epidermal growth factor receptor recycling from early endosomes through Arp2/3 complex and cortactin. Mol. Biol. Cell. 19, 17-29
63. Salazar, G., and González, A. (2002) Novel mechanism for regulation of epidermal growth factor receptor endocytosis revealed by protein kinase A inhibition. Mol. Biol. Cell. 13, 1677-1693
64. Norambuena, A., Metz, C, and Jung, J. E., Silva, A., Otero, C, Cancino, J., Retamal, C, Valenzuela, J. C, Soza, A., and González, A. (2010) Phosphatidic acid induces ligand-independent epidermal growth factor receptor endocytic traffic through PDE4 activation. Mol. Biol. Cell. 21,
65. Kaneko, T., Maeda, A., Takefuji, M., Aoyama, H., Nakayama, M., Kawabata, S., Kawano, Y., Iwamatsu, A., Amano, M., and Kaibuchi, K. (2005) Rho mediates endocytosis of epidermal growth factor receptor through phosphorylation of endophilin A1 by Rho-kinase. Genes Cells. 10, 973-987
66. Nishimura, Y., Yoshioka, K., Bernard, O., Bereczky, B., and Itoh, K. (2006) A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem. Cell Biol. 126, 627-638
67. Idkowiak-Baldys, J., Baldys, A., and Raymond, J. R., and Hannun, Y. A. (2009) Sustained receptor stimulation leads to sequestration of recycling endo-somes in a classical protein kinase C- and phospholipase D-dependent manner. J. Biol. Chem. 284, 22322-22331
68. Shen, Y., Xu, L., and Foster, D. A. (2001) Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell Biol. 21, 595-602
69. Antonescu, C. N., Danuser, G., and Schmid, S. L. (2010) Phosphatidic acid plays a regulatory role in clathrin-mediated endocytosis. Mol. Biol. Cell. 21, 2944-2952
70. Cai, J., and Crotty, T. M., Reichert, E., Carraway, K. L., 3rd, Stafforini, D. M., and Topham, M. K. (2010) Diacylglycerol kinase S and protein kinase C(a) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8. J. Biol. Chem. 285, 6952-6959
71. Kasai, A., Shima, T., and Okada, M. (2005) Role of Src family tyrosine kinases in the down-regulation of epidermal growth factor signaling in PC12 cells. Genes Cells. 10, 1175-1187
72. Medts, T., de Diesbach, P., Cominelli, A., N'Kuli, F., Tyteca, D., and Courtoy, P. J. (2010) Acute ligand-independent Src activation mimics low EGF-induced EGFR surface signaling and redistribution into recycling endosomes. Exp. Cell Res. 316, 3239-3253
73. Ware, M. F., and Tice, D. A., Parsons, S. J., and Lauffenburger, D. A. (1997) Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor. J. Biol. Chem. 272, 30185-30190
74. Helikar, T., Kochi, N., Kowal, B., Dimri, M., Naramura, M., Raja, S. M., Band, V., Band, H., and Rogers, J. A. (2013) A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells. PLoS One. 8, e61757
75. Ouyang, X., Gulliford, T., and Epstein, R.J. (1998) The duration of phor-bol-inducible ErbB2 tyrosine dephosphorylation parallels that of receptor endocytosis rather than threonine-686 phosphorylation: implications for the physiological role of protein kinase C in growth factor receptor signaling. Carcinogenesis 19, 2013-2019
76. Magnifico, A., Albano, L., Campaner, S., Campiglio, M., Pilotti, S., Ménard, S., and Tagliabue, E. (2007) Protein kinase Ca determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res. 67, 5308-5317
77. Feng, X., Zhang, J., Barak, L. S., Meyer, T., and Caron, M. G., and Hannun, Y. A. (1998) Visualization of dynamic trafficking of a protein kinase C βII/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitization. J. Biol. Chem. 273, 10755-10762
78. Raja, S. M., and Clubb, R. J., Ortega-Cava, C., Williams, S. H., and Bailey, T. A., Duan, L., Zhao, X., Reddi, A. L., Nyong, A. M., Natarajan, A., Band, V., and Band, H. (2011) Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol. Ther. 11, 263-276
79. Bonita, D. P., Miyake, S., Lupher, M. L., Jr., Langdon, W. Y., and Band, H. (1997) Phosphotyrosine binding domain-dependent up-regulation of the platelet-derived growth factor receptor α signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity. Mol. Cell. Biol. 17, 4597-4610
80. Harari, D., and Yarden, Y. (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114
81. Wang, X. Q., Yan, Q., Sun, P., Liu, J. W., Go, L., and McDaniel, S. M., and Paller, A. S. (2007) Suppression of epidermal growth factor receptor signaling by protein kinase C-a activation requires CD82, caveolin-1, and ganglioside. Cancer Res. 67, 9986-9995
82. Alessi, D. R. (1997) The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β= (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121-123
83. Han, Z., Pantazis, P., Lange, T. S., and Wyche, J. H., and Hendrickson, E. A. (2000) The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C. Cell Death Differ. 7, 521-530
84. Standaert, M. L., Bandyopadhyay, G., Antwi, E. K., and Farese, R. V. (1999) RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin. Endocrinology 140, 2145-2151
85. Beltman, J., McCormick, F., and Cook, S. J. (1996) The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J. Biol. Chem. 271, 27018-27024
86. Zeng, L., Webster, S.V., and Newton, P. M. (2012) The biology of protein kinase C Adv. Exp. Med. Biol. 740, 639-661
87. Konopatskaya, O., and Poole, A. W. (2010) Protein kinase Cα: disease regulator and therapeutic target. Trends Pharmacol. Sci. 31, 8-14
88. Rosse, C, Linch, M., Kermorgant, S., Cameron, A. J., Boeckeler, K., and Parker, P. J. (2010) PKC and the control of localized signal dynamics. Nat Rev. Mol. Cell Biol. 11, 103-112
89. Le, X. F., Marcelli, M., McWatters, A., Nan, B., and Mills, G. B., O'Brian, C. A., and Bast, R. C, Jr. (2001) Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase Ca activity. Oncogene 20, 8258-8269
90. Alvi, F., Idkowiak-Baldys, J., Baldys, A., and Raymond, J. R., and Hannun, Y. A. (2007) Regulation of membrane trafficking and endocytosis by protein kinase C: emerging role of the pericentrion, a novel protein kinase C-de-pendent subset of recycling endosomes. Cell Mol. Life Sci. 64, 263-270
91. Becker, K. P., and Hannun, Y. A. (2003) cPKC-dependent sequestration of membrane-recycling components in a subset of recycling endosomes. J. Biol. Chem. 278, 52747-52754
92. Schweitzer, J. K., and Sedgwick, A. E., and D'Souza-Schorey, C. (2011) ARF6-mediated endocytic recycling impacts cell movement, cell division and lipid homeostasis. Semin. Cell Dev. Biol. 22, 39-47
93. Padival, A. K., and Hawkins, K. S., and Huang, C (2004) High glucose-induced membrane translocation of PKC βI is associated with Arf6 in glomerular mesangial cells. Mol. Cell. Biochem. 258, 129-135
94. Melendez, A. J., and Harnett, M. M., and Allen, J. M. (2001) Crosstalk between ARF6 and protein kinase Calpha in Fc(7)RI-mediated activation of phospholipase D1. Curr. Biol. 11, 869-874
95. Gabriel, L., Lvov, A., Orthodoxou, D., Rittenhouse, A. R., and Kobertz, W. R., and Melikian, H. E. (2012) The acid-sensitive, anesthetic-activated potassium leak channel, KCNK3, is regulated by 14-3-3β-dependent, protein kinase C (PKC)-mediated endocytic trafficking. J. Biol. Chem. 287, 32354-32366
96. Katz, M., Amit, I., and Yarden, Y. (2007) Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta. 1773, 1161-1176
97. Keshamouni, V. G., and Mattingly, R. R., and Reddy, K. B. (2002) Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-S. J. Biol. Chem. 277, 22558-22565
98. Allen-Petersen, B. L., Carter, C. J., and Ohm, A. M., and Reyland, M. E. (2014) Protein kinase CS is required for ErbB2-driven mammary gland tumor-igenesis and negatively correlates with prognosis in human breast cancer. Oncogene 33, 1306-1315
99. Urtreger, A. J., and Kazanietz, M. G., and Bal de Kier Joffé, E. D. (2012) Contribution of individual PKC isoforms to breast cancer progression. IUBMBLife. 64, 18-26
100. Tonetti, D. A., Gao, W., Escarzaga, D., Walters, K., Szafran, A., and Coon, J. S. (2012) PKCa and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int. J. Breast Cancer. 2012, 740353
101. Lonne, G. K., Cornmark, L., Zahirovic, I. O., Landberg, G., Jirstrom, K., and Larsson, C. (2010) PKCa expression is a marker for breast cancer aggressiveness. Mol. Cancer 9, 76-98
102. Tan, M., Li, P., Sun, M., Yin, G., and Yu, D. (2006) Upregulation and activation of PKCa by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors. Oncogene 25, 3286-3295
103. Recktenwald, C. V., Leisz, S., Steven, A., Mimura, K., Müller, A., Wulfänger, J., Kiessling, R., and Seliger, B. (2012) HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J. Biol. Chem. 287, 24320-24329
104. Rafn, B., and Nielsen, C. F., Andersen, S. H., Szyniarowski, P., Corcelle-Termeau, E., Valo, E., Fehrenbacher, N., Olsen, C. J., Daugaard, M., Egebjerg, C., Bøttzauw, T., Kohonen, P., Nylandsted, J., Hautaniemi, S., Moreira, J., Jäättelä, M., and Kallunki, T. (2012) ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol. Cell. 45, 764-776
105. Gordon, L. I., and Burke, M. A., Singh, A. T., Prachand, S., Lieberman, E. D., Sun, L., and Naik, T. J., Prasad, S. V., and Ardehali, H. (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J. Biol. Chem. 284, 2080-2087
106. Li-Ping, Z., Da-Lei, Z., Jian, H., Liang-Quan, X., Ai-Xia, X., Xiao-Yu, D., Dan-Feng, T., and Yue-Hui, Z. (2010) Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways. Reprod. Biol. Endocrinol. 8:66, pp1-9, 7827-7828
107. Citri, A., and Yarden, Y. (2006) EGF-ERBB signaling: toward the systems level. Nat Rev. Mol. Cell Biol. 7, 505-516
108. Idkowiak-Baldys, J., Becker, K. P., Kitatani, K., and Hannun, Y. A. (2006) Dynamic sequestration of the recycling compartment by classical protein kinase C.J. Biol. Chem. 281, 22321-22331
109. Lum, M. A., and Pundt, K. E., Paluch, B.E., Black, A. R., and Black, J. D. (2013) Agonist-induced down-regulation of endogenous protein kinase Ca through an endolysosomal mechanism. J. Biol. Chem. 288, 13093-13109
110. Lum, M. A., and Balaburski, G. M., Murphy, M. E., Black, A. R., and Black, J. D. (2013) Heat Shock Proteins Regulate Activation-Induced Proteasomal Degradation of the Mature Phosphorylated Form of Protein Kinase C. J. Biol. Chem. 288, 27112-27127
111. Marcotte, R., Zhou, L., Kim, H., Roskelly, C. D., and Muller, W. J. (2009) c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol. Cell. Biol. 29, 5858-5871
112. Chung, B. M., and Raja, S. M., Clubb, R. J., Tu, C, George, M., Band, V., and Band, H. (2009) Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol. 10, 84
113. Chung, B. M., Dimri, M., George, M., Reddi, A.L., Chen, G., Band, V., and Band, H. (2009) The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 28, 1821-1832
114. Lanzetti, L., and Di Fiore, P. P. (2008) Endocytosis and cancer: an 'insider' network with dangerous liaisons. Traffic 9, 2011-2021
115. Rusin, A., Krawczyk, Z., Grynkiewicz, G., Gogler, A., Zawisza-Puchałka, J., Szeja, W. (2010) Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim Pol. 57, 23-34